ChemoMetec A/S (CHEMM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ChemoMetec A/S (CHEMM) has a cash flow conversion efficiency ratio of 0.139x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr90.64 Million ≈ $14.18 Million USD) by net assets (Dkr652.59 Million ≈ $102.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ChemoMetec A/S - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how ChemoMetec A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CHEMM liabilities breakdown for a breakdown of total debt and financial obligations.
ChemoMetec A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ChemoMetec A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chutian Dragon Co Ltd
SHE:003040
|
0.053x |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
0.027x |
|
Cello World Limited
NSE:CELLO
|
0.010x |
|
HangZhou Radical Energy Saving Technology Co Ltd
SHE:300652
|
0.065x |
|
Sungho Electronics Corp
KQ:043260
|
0.063x |
|
GCI Liberty, Inc.
NASDAQ:GLIBK
|
0.045x |
|
Ulker Biskuvi Sanayi AS
IS:ULKER
|
0.050x |
|
TOA PAINT (THAILAND)
BK:TOA-R
|
N/A |
Annual Cash Flow Conversion Efficiency for ChemoMetec A/S (2005–2025)
The table below shows the annual cash flow conversion efficiency of ChemoMetec A/S from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see ChemoMetec A/S stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | Dkr673.36 Million ≈ $105.35 Million |
Dkr207.45 Million ≈ $32.46 Million |
0.308x | +35.01% |
| 2024-06-30 | Dkr565.32 Million ≈ $88.45 Million |
Dkr129.00 Million ≈ $20.18 Million |
0.228x | -21.09% |
| 2023-06-30 | Dkr533.04 Million ≈ $83.40 Million |
Dkr154.15 Million ≈ $24.12 Million |
0.289x | -41.59% |
| 2022-06-30 | Dkr357.20 Million ≈ $55.89 Million |
Dkr176.86 Million ≈ $27.67 Million |
0.495x | +21.59% |
| 2021-06-30 | Dkr264.98 Million ≈ $41.46 Million |
Dkr107.90 Million ≈ $16.88 Million |
0.407x | +14.64% |
| 2020-06-30 | Dkr202.75 Million ≈ $31.72 Million |
Dkr72.02 Million ≈ $11.27 Million |
0.355x | +5.59% |
| 2019-06-30 | Dkr173.34 Million ≈ $27.12 Million |
Dkr58.31 Million ≈ $9.12 Million |
0.336x | -3.44% |
| 2018-06-30 | Dkr73.01 Million ≈ $11.42 Million |
Dkr25.44 Million ≈ $3.98 Million |
0.348x | +129.87% |
| 2017-06-30 | Dkr64.38 Million ≈ $10.07 Million |
Dkr9.76 Million ≈ $1.53 Million |
0.152x | -49.91% |
| 2016-06-30 | Dkr56.85 Million ≈ $8.89 Million |
Dkr17.20 Million ≈ $2.69 Million |
0.303x | +4.70% |
| 2015-06-30 | Dkr46.35 Million ≈ $7.25 Million |
Dkr13.39 Million ≈ $2.10 Million |
0.289x | +127.07% |
| 2014-06-30 | Dkr44.53 Million ≈ $6.97 Million |
Dkr5.67 Million ≈ $886.64K |
0.127x | -29.63% |
| 2013-06-30 | Dkr43.23 Million ≈ $6.76 Million |
Dkr7.82 Million ≈ $1.22 Million |
0.181x | -12.56% |
| 2012-06-30 | Dkr42.86 Million ≈ $6.71 Million |
Dkr8.87 Million ≈ $1.39 Million |
0.207x | +39.88% |
| 2011-06-30 | Dkr52.71 Million ≈ $8.25 Million |
Dkr7.79 Million ≈ $1.22 Million |
0.148x | +15.98% |
| 2010-06-30 | Dkr52.62 Million ≈ $8.23 Million |
Dkr6.71 Million ≈ $1.05 Million |
0.127x | -53.18% |
| 2009-06-30 | Dkr56.31 Million ≈ $8.81 Million |
Dkr15.33 Million ≈ $2.40 Million |
0.272x | +950.04% |
| 2008-06-30 | Dkr51.71 Million ≈ $8.09 Million |
Dkr1.34 Million ≈ $209.81K |
0.026x | +225.62% |
| 2007-06-30 | Dkr39.34 Million ≈ $6.15 Million |
Dkr-812.00K ≈ $-127.04K |
-0.021x | -170.06% |
| 2006-06-30 | Dkr16.50 Million ≈ $2.58 Million |
Dkr486.00K ≈ $76.04K |
0.029x | +18.05% |
| 2005-06-30 | Dkr-11.34 Million ≈ $-1.77 Million |
Dkr-283.00K ≈ $-44.28K |
0.025x | -- |
About ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, an… Read more